Device Trial Radar · NCT06733246
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Nov 12, 2024
Primary completion
May 30, 2027
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Ceretrieve Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure. This means to assess that the use with the Ceretrieve neuro-thrombectomy device that is designed to treat acute ischemic stroke patients raises no safety concerns and that it is found to be effective when it is used according to its intended purpose, which is revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (involving the internal carotid artery, middle cerebral artery- M1 and M2 segments, basilar, and vertebral arteries). The study researchers will compare the efficacy and safety results of this study to data derived from the literature of FDA approved neuro-thrombectomy devices. The study hypothesis is that The Ceretrieve device would achieve successful reperfusion performance shall be similar to the safety \& performance derived from the literature. The primary outcomes that will be measures are: Performance: Successful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia (mTICI) score 2b-3 within three passes of the Ceretrieve system without any rescue. Safety: Symptomatic intra-cranial hemorrhage within 24 (18-36) hours of the study procedure. Patients who will participate in this study will be followed for a time period of 3 months. After discharge from the medical center, they will be asked to arrive to a one visit at the clinic for safety data collection and evaluation.
Conditions
- Acute Ischemic Stroke
Interventions
Aspiration 0Device
Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Successful Reperfusion (mTICI 2b-3) Within Three Passes Without Rescue TherapyTime frame: intra-procedural
- Number of Participants With Symptomatic Intracranial Hemorrhage Within 24 (18-36) Hours Post-ProcedureTime frame: 24 (18-36) hours post procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Heidelberg University Hospital
Heidelberg, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.